Clinical-stage biotechnology company that applies human genetics to develop small-molecule precision medicines for severe rare diseases. Setara was formed as a spinout of Actio Biosciences following Jazz Pharmaceuticals' acquisition of the company, carrying forward Actio's remaining pipeline under co-founder and human genetics expert David Goldstein. Its lead program STAR-0871, an oral TRPV4 inhibitor, is in development for Charcot-Marie-Tooth disease type 2C and overactive bladder, and its 'one to many' strategy aims to extend insights from rare genetic diseases into more prevalent conditions such as genetic epilepsy and migraine.
1
Round
1
Industry
5
Tags
Oct 30, 2026
Latest raise
Funding activity · 1 round
Oct 30, 2026
$90M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
